Navigation Links
W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Date:4/7/2008

AURORA, ON, April 7 /PRNewswire-FirstCall/ - Helix BioPharma Corp. (TSX: HBP / Frankfurt: WKN 918864)

Helix BioPharma Corp. today announced that the board of directors has increased the authorized number of directors from six to seven and has appointed Mr. W. Thomas Hodgson as director to fill the newly created position. Mr. Hodgson will also serve as chair of the three member Audit Committee, replacing Mr. Jack Kay who previously held the position.

Mr. Hodgson is currently senior partner and chairman of Greenbrook Capital Partners and acts as an advisor to the chairman of Magna Entertainment Corp. Mr. Hodgson's prior roles include senior positions with Canadian financial institutions and U.K. based companies.

Donald Segal, chief executive officer of Helix BioPharma, said, "Tom's diverse professional background and capital markets experience will be an invaluable resource to the board. In addition, his extensive knowledge of complex financial matters makes him ideally suited to chair our audit committee. We look forward to his contributions."

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX under the symbol "HBP" and quoted on the Frankfurt, Berlin, Munich and Stuttgart Stock Exchanges under the same symbol.

The Toronto Stock Exchange has not reviewed and does not accept

responsibility for the adequacy or accuracy of the content of this News

Release.


'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Thomas W. Burke, MD, Elected 40th President of the Society of Gynecologic Oncologists
2. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
3. Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions
4. Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetixs Medical Advisory Board
5. Neurocrine Biosciences to Present at the Thomas Weisel Partners Healthcare Conference
6. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
7. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
8. Kendle to Present at Thomas Weisel Partners Healthcare Conference 2007
9. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
10. Cepheid to Present at Thomas Weisel Partners Healthcare Conference
11. Luminex Corporation to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... -- In Atlanta, it seems everyone has a chance to express ... an expressive and dynamic community unlike any other. The businesses ... it. With their newest salon in ... carry on that tradition with a unique, fresh approach to ... is the newest of 13 nationwide locations, each of them ...
(Date:2/23/2017)... San Antonio, TX (PRWEB) , ... February 23, ... ... and Drug Administration (FDA) de novo clearance to begin marketing the SPEAC® System, ... is indicated for adults at home or in healthcare facilities during periods of ...
(Date:2/23/2017)... ... February 23, 2017 , ... Today, researchers can fast-track sample ... acid, and/or other biomarkers or SNPs of interest) using one, easy-to-collect saliva sample. ... the relationship between insulin and other relevant biomarkers can be extensively studied through ...
(Date:2/23/2017)... 2017 Aviva Systems Biology Corporation (ASB) ... of GenWay Biotech Incorporated, a protein solutions and ... offering for both the research and diagnostic markets. ... enhance capabilities for both entities. GenWay,s 18 years of ... nicely complement ASB,s objective to become a leading ...
Breaking Biology Technology:
(Date:2/8/2017)... 7, 2017  Aware, Inc. (NASDAQ: AWRE ), ... financial results for its quarter and year ended December 31, ... 2016 was $3.9 million compared to $6.9 million in the ... of 2016 was $0.6 million compared to $2.6 million in ... quarter of 2016 was $0.5 million, or $0.02 per diluted ...
(Date:2/7/2017)... 7, 2017   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... innovative, highly flexible and award winning eClinical solution, is ... iMedNet is a proven Software-as-a-Service (SaaS) clinical research ... (EDC), but also delivers an entire suite of eClinical ...
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute announced ... Larry Schlesinger as the Institute,s new President and ... effective May 31, 2017. He is currently the Chair of ... the Center for Microbial Interface Biology at Ohio State University. ... the new President and CEO of Texas Biomed," said Dr. ...
Breaking Biology News(10 mins):